Eisai & Biogen announce update on regulatory review of MAA for lecanemab to treat early Alzheimer’s disease by European Commission: Tokyo Wednesday, April 16, 2025, 11:00 Hrs [I ...

VulnCheck, the exploit intelligence company, today pledged its full support behind MITRE and the decades' worth of positive contributions that MITRE has made to the entire cybersecurity community ...

A drug that targets an underlying cause of Alzheimer's disease being commercialized by Eisai and Biogen has received marketing approval from the European Commission.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the European Commission (EC) has granted the amyloid-beta (A?) monoclonal antibody Leqembi® ...

The European Commission has today communicated that it has granted BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai's application for Marketing Authorization of ...

WASHINGTON, April 15, 2025 (GLOBE NEWSWIRE) -- According to national security advisor and legal strategist Jim Rickards, America may be days away from opening what he calls the country's "greatest ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild ...

The antibody lecanemab is the first authorized therapy in Europe that targets the underlying process of Alzheimer's, rather than only treating symptoms.

The European Commission has granted the amyloid-beta monoclonal antibody Leqembi Marketing Authorization in the European Union. Lecanemab is ...

The European Commission has for the first time approved an Alzheimer's therapy that targets the underlying disease processes.

The European Commission has approved the antibody lecanemab to treat Alzheimer's, the first time it has authorized a therapy which targets the underlying disease processes, rather than just the ...